Skip to main
NDRA

NDRA Stock Forecast & Price Target

NDRA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ENDRA Life Sciences Inc. is developing the Thermo Acoustic Enhanced UltraSound (TAEUS) technology, aimed at visualizing tissue in a manner similar to MRI, but at a lower cost and at the point of patient care. The anticipated FDA approval within the next year, underpinned by a favorable net present value (NPV) analysis, suggests substantial potential for the stock's appreciation. This innovative technology has the capacity to provide earlier diagnoses and more accurate monitoring of chronic liver conditions such as Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), addressing a significant unmet need in a market affecting over one billion individuals globally.

Bears say

ENDRA Life Sciences Inc. reported a net loss of $1.6 million in the latest quarter, resulting in an earnings per share (EPS) of $(2.10), which was worse than the previous estimate of $(1.95). The company also faced a recurring net loss of $1.2 million with an EPS of $(1.71), not aligning with the earlier expectations of $(2.27). The financial outlook is further challenged by various risks, including balance sheet and liquidity issues, potential failures in clinical trials or regulatory approvals, difficulties in commercialization and reimbursement, as well as competition and shifting macroeconomic conditions.

NDRA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ENDRA Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ENDRA Life Sciences (NDRA) Forecast

Analysts have given NDRA a Strong Buy based on their latest research and market trends.

According to 1 analysts, NDRA has a Strong Buy consensus rating as of Mar 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ENDRA Life Sciences (NDRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.